Summary
Until recently, cholecystectomy was the only treatment available for symptomatic gallstone disease. During the past 20 years, better understanding of the pathogenesis of cholesterol gallstone disease has led to alternative nonsurgical methods for treating gallstones in selected groups of patients.
Use of 2 naturally occurring bile acids, chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA), was reported in 1972 and 1975, respectively, for successful dissolution of cholesterol gallstones in humans. Both these bile acids act by reducing cholesterol secretion in bile, thus enabling it to solubilise more cholesterol from the stone surface. Micellar solubilisation is involved, together with liquid crystal formation in the case of UDCA. Having been extensively studied in clinical trials to assess efficacy and safety, both these compounds are now available for general use.
The efficacy of CDCA can be enhanced by single bedtime dose administration and by taking a low cholesterol diet. Bedtime administration also enhances the effect of a suboptimal dose of UDCA. CDCA induces dose-related diarrhoea and hypertransaminaemia, and UDCA can induce calcification of gallstones, thus rendering them resistant to medical dissolution. A combination of the 2 bile acids at half the recommended dose for each has become an accepted practice for reducing adverse effects, and this may also enhance efficacy.
One of the main problems of bile acid therapy is that dissolution of gallstones is a very slow process. Use of extracorporeal Shockwave lithotripsy (ESWL) to break the stones into smaller fragments, with concurrent use of bile acids, has been shown to speed dissolution rate and to achieve complete gallstone dissolution in 78% of selected cases within 12 months. Experience in the use of ESWL is limited at this stage and the equipment is not generally available. Another method of achieving quick dissolution of gallstones is direct instillation of liquid ether, methyltert-butyl-ether (MTBE), via a pig-tail catheter inserted percutaneously into the gallbladder cavity.
For any nonsurgical treatment to be effective the stones should be radiolucent and the gallbladder should opacify well on oral cholecystogram. Once treatment with bile acids is discontinued after confirmed gallstone dissolution, bile returns to its original supersaturated state with respect to cholesterol and stones recur in approximately 50% of cases. It is therefore necessary to follow up these patients on a long term basis with regular ultrasound examination in order to detect early recurrence. As no simple method of preventing gallstone recurrence is available at present these patients should be treated with a repeat course of bile acid therapy at the earliest possible time after recurrence.
Similar content being viewed by others
References
Barbara L, Sama C, Morselli-Labate AM, Taroni F, Rusticali AG, et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology 7: 913–917, 1987
Bell GD, Dowling RH, Whitney B, Sutor DJ. The value of radiology in predicting gallstone type when selecting patients for medical treatment. Gut 16: 359–364, 1975
Bell GD, Sutor DJ, Whitney B, Dowling RH. Factors influencing human gallstone dissolution in monkey, dog and human bile. Gut 13: A865, 1972
Carey MC, Park Y-H, Igimi H, Salvioli G. Factors affecting speed of gallstone dissolution during litholytic therapy. In Paumgartner et al. (Eds) Enterohepatic circulation of bile acid and sterol metabolism, pp. 321–331, MTP Press, Lancaster, 1985
Ceygan P, Stiehl A, Readsch R, Stietz H, Kommerell B. Dissolution of cholesterol gallstones by combination of urso/cheno versus urso. In Paumgartner et al. (Eds) Enterohepatic circulation of bile acids and sterol metabolism, pp. 351–353, MTP Press, Lancaster, 1985
Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. New England Journal of Medicine 286: 1–8, 1972
Dolgin SM, Schwartz JS, Kressel HY, Soloway RD, Miller WT, et al. Identification of patients with cholesterol or pigment stones by discriminant analysis of radiological features. New England Journal of Medicine 304: 808–811, 1981
Doran J, Keighley MRB, Bell GD. A possible treatment for cholesterol gallstones. Gut 20: 312–317, 1979
Fromm H, Roat JN, Gonzabo V, Sarva RJ, Farivar S. Comparative efficacy and side effects of ursodeoxycholic acid and chenodeoxycholic acid in dissolving gallstones. Gastroenterology 85: 1257–1264, 1983
Hardison WG, Grundy SM. Effect of ursodeoxycholate and its taurate conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology 87: 130–135, 1984
Hood K, Gleeson D, Ruppin DC, Dowling RH, and the British Belgian Gallstone Study Group. Can gallstone recurrence be prevented? The British/Belgian post-dissolution trial. Gastroenterology 94: 548, 1988
Kupfer RM, Maudgal DP, Northfield TC. Gallstone dissolution rate during chenic acid therapy: effect of bedtime administration plus low cholesterol diet. Digestive Diseases and Sciences 27: 1025–1029, 1982
Lanzini A, Jazrawi RP, Kupfer RM, Maudgal DP, Joseph AEA, et al. Gallstone recurrence after medical dissolution: an overestimated threat? Journal of Hepatology 3: 241–246, 1986
Makino I, Hashimoto H, Shinozaki K, Nakagawa S. Dissolution of cholesterol gallstone by ursodeoxycholic acid. Japanese Journal of Gastroenterology 72: 690–702, 1975
Maton PN, Iser JH, Reuben A, Saxton A, Murphy HM, et al. The final outcome of CDCA treatment in 125 patients with radiolucent gallstones: factors influencing efficacy, withdrawal, symptoms and side effects and post-dissolution recurrence. Medicine 61: 85–96, 1982
Maudgal DP, Kupfer RM, Northfield TC Factors affecting gallstone dissolution rate during chenic acid therapy. Gut 24: 7–10, 1983
Mok HYI, Bell GD, Dowling RH. Effect of different doses of chenodeoxycholic acid on bile lipid composition and frequency of side effects in patients with gallstones. Lancet 2: 253–257, 1974
Newman HF, Northorp JD. The autopsy incidence of gallstones. International Abstracts in Surgery 109: 1–13, 1959
Northfield TC, Lanzini A, Jazrawi R, Maudgal DP, Kupfer RM. Methods for improving the efficacy of litholytic therapy. In Paumgartner et al. (Eds) Enterohepatic circulation of bile acids and sterol metabolism, pp. 335–350, MTP Press, Lancaster, 1985
Roda E, Bazzoli F, Labate AMN, Mazzella G, Roda A, et al. Ursodeoxycholic acid vs chenodeoxycholic acid as cholesterol gallstone dissolving agent: a comparative study. Hepatology 2: 804–810, 1982
Ruppin DC, Dowling RH. Is recurrence inevitable after gallstone dissolution by bile acid treatment? Lancet 1: 181–185, 1982
Salen G, Nicolau G, Shefer S. Chenodeoxycholic acid inhibits elevated hepatic HMG-CoA reductase activity in subjects with gallstones. Clinical Research 21: 523, 1973
Sauerbruch T, Delius M, Paumgartner G, Holl J, Wess O, et al. Fragmentation of gallstones by extra-corporeal shock waves. New England Journal of Medicine 3314: 818–822, 1986
Schoenfield LJ, Lachin JM, the Steering Committee and the National Co-operative Gallstone Study Group. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the national co-operative gallstone study. Annals of Internal Medicine 95: 257–282, 1981
Thistle JL, May GR, Bender CE, Williams HJ, Le Roy AJ, et al. Dissolution of cholesterol gallbladder stones by methyl tertbutyl ether administered by percutaneous transhepatic catheter. New England Journal of Medicine 320: 633–639, 1989
Toulet J, Rousselet J, Viteau JM, Duchon Y, Pagniez R, et al. Récidives et prévention des récidives après dissolution de la lithiases vésiculaire par l’acide chénodésoxycholique chez 22 patients. Gastroentérologie Clinique et Biologique 7: 605–609, 1983
Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 27: 95–131, 1984
Wolpers C. Morphologie der gallsteine. Leber Magen Darm 4: 43–57, 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maudgal, D.P., Northfield, T.C. A Practical Guide to the Nonsurgical Treatment of Gallstones. Drugs 41, 185–192 (1991). https://doi.org/10.2165/00003495-199141020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199141020-00004